MediWound has commenced a pivotal, multicentre Phase III VALUE trial to assess its bioactive debridement therapy, EscharEx, ...
Use precise geolocation data and actively scan device characteristics for identification. This is done to store and access ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback